Treatment of Yersiniosis in Reactive Arthritis
Yersiniosis can be followed by reactive arthritis (ReA) — an aseptic joint inflammation arising after the infection. This presentation requires a targeted approach that addresses both the joint manifestations and the underlying infectious status.
Reactive arthritis in the setting of Yersiniosis is an aseptic arthritis: the joint inflammation is not caused by direct joint infection and is generally self-limiting. The presence of active yersiniosis at the time of evaluation is a key clinical distinction that shapes management.
Relief of joint pain is the primary management focus, addressed through anti-inflammatory therapy. When active yersiniosis is documented, an antibiotic-based component is added to the regimen with the aim of shortening the overall clinical course.
Complete regimen detail — agents, sequencing, and criteria — is in the structured protocol.Faster remission and relief of joint pain by three months.
References
DOI: 10.3390/microorganisms13051133
Since ReA is an aseptic arthritis, it does not require antibiotic treatment and is usually self-limiting.
Joint pain may well respond to NSAIDs or glucocorticosteroids, but chronic ReA may require the introduction of disease-modifying antirheumatic drugs (DMARDs).
However, in active yersiniosis, the implementation of ciprofloxacin results in the shortening of symptoms.
Ciprofloxacin 500 mg twice daily orally compared with placebo for three months causes faster remission and pain relief compared with the group without antibiotics.
View source ↗